|Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping|
DM Sado, SK White, SK Piechnik, SM Banypersad, T Treibel, G Captur, ...
Circulation: Cardiovascular Imaging 6 (3), 392-398, 2013
|Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor|
I Fraser, D Hughes, S Gordon
Nature 364 (6435), 343-346, 1993
|Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa|
DA Hughes, PM Elliott, J Shah, J Zuckerman, G Coghlan, J Brookes, ...
Heart 94 (2), 153-158, 2008
|Natural history of Fabry disease in females in the Fabry Outcome Survey|
PB Deegan, AF Baehner, MAB Romero, DA Hughes, C Kampmann, ...
Journal of medical genetics 43 (4), 347-352, 2006
|The macrophage scavenger receptor type A is expressed by activated macrophages and protects the host against lethal endotoxic shock|
R Haworth, N Platt, S Keshav, D Hughes, E Darley, H Suzuki, Y Kurihara, ...
The Journal of experimental medicine 186 (9), 1431-1439, 1997
|Treatment of Fabry’s disease with the pharmacologic chaperone migalastat|
DP Germain, DA Hughes, K Nicholls, DG Bichet, R Giugliani, WR Wilcox, ...
New england journal of medicine 375 (6), 545-555, 2016
|Macrophage recruitment during limb development and wound healing in the embryonic and foetal mouse|
J Hopkinson-Woolley, D Hughes, S Gordon, P Martin
Journal of cell science 107 (5), 1159-1167, 1994
|Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease|
DM Sado, AS Flett, SM Banypersad, SK White, V Maestrini, G Quarta, ...
Heart 98 (19), 1436-1441, 2012
|Identification of macrophages and dendritic cells in the osteopetrotic (op/op) mouse|
MD Witmer-Pack, DA Hughes, G Schuler, L Lawson, A McWilliam, K Inaba, ...
Journal of cell science 104 (4), 1021-1029, 1993
|Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study|
DA Hughes, K Nicholls, SP Shankar, G Sunder-Plassmann, D Koeller, ...
Journal of medical genetics 54 (4), 288-296, 2017
|Murine macrophage scavenger receptor: in vivo expression and function as receptor for macrophage adhesion in lymphoid and non‐lymphoid organs|
DA Hughes, IP Fraser, S Gordon
European journal of immunology 25 (2), 466-473, 1995
|Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document|
M Biegstraaten, R Arngrímsson, F Barbey, L Boks, F Cecchi, PB Deegan, ...
Orphanet journal of rare diseases 10 (1), 1-10, 2015
|Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease|
JS Shah, DA Hughes, B Sachdev, M Tome, D Ward, P Lee, AB Mehta, ...
The American journal of cardiology 96 (6), 842-846, 2005
|Multiple myeloma: causes and consequences of delay in diagnosis|
CC Kariyawasan, DA Hughes, MM Jayatillake, AB Mehta
QJM: An International Journal of Medicine 100 (10), 635-640, 2007
|Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study|
CJ Hendriksz, B Burton, TR Fleming, P Harmatz, D Hughes, SA Jones, ...
Journal of inherited metabolic disease 37 (6), 979-990, 2014
|Prevalence of Anderson–Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson–Fabry Disease Survey|
P Elliott, R Baker, F Pasquale, G Quarta, H Ebrahim, AB Mehta, ...
Heart 97 (23), 1957-1960, 2011
|Macrophage-colony-stimulating factor selectively enhances macrophage scavenger receptor expression and function.|
WJ De Villiers, IP Fraser, DA Hughes, AG Doyle, S Gordon
The Journal of experimental medicine 180 (2), 705-709, 1994
|Fabry disease and the skin: data from FOS, the Fabry outcome survey|
CH Orteu, T Jansen, O Lidove, R Jaussaud, DA Hughes, G Pintos‐Morell, ...
British Journal of Dermatology 157 (2), 331-337, 2007
|Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation–positive cohort|
M Beavan, A McNeill, C Proukakis, DA Hughes, A Mehta, AHV Schapira
JAMA neurology 72 (2), 201-208, 2015
|Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage|
MWJ Cleeter, KY Chau, C Gluck, A Mehta, DA Hughes, M Duchen, ...
Neurochemistry international 62 (1), 1-7, 2013